Selection of Iodine 125 for the Collaborative Ocular Melanoma Study

Physics: Low-Energy Brachytherapy Physics

“…After comparing various isotopes (Ra-226, Au-198, Co-60, Ir-192, and I-125, as well as tantalum-182 and ruthenium-10), the Collaborative Ocular Melanoma Study chose I-125 ophthalmic plaque radiation therapy to treat medium-sized choroidal melanomas. In the study, 85 Gy was prescribed at the apex of tumor for 3-7 days at a dose rate of 0.42-1.05 Gy h −1 [35,36]. Some researchers chose to deliver the apical dose of 73.3 Gy over 5-7 days using Pd-103 and reported a favorable outcome [37][38][39].…”

Physics: Low-Energy Brachytherapy Physics

“…After comparing various isotopes (Ra-226, Au-198, Co-60, Ir-192, and I-125, as well as tantalum-182 and ruthenium-10), the Collaborative Ocular Melanoma Study chose I-125 ophthalmic plaque radiation therapy to treat medium-sized choroidal melanomas. In the study, 85 Gy was prescribed at the apex of tumor for 3-7 days at a dose rate of 0.42-1.05 Gy h −1 [35,36]. Some researchers chose to deliver the apical dose of 73.3 Gy over 5-7 days using Pd-103 and reported a favorable outcome [37][38][39].…”

Iodine-125 Brachytherapy for Uveal Melanoma: A Systematic Review of Radiation Dose

“…This dose was adjusted (originally 100.0 Gy) after the Task Group (TG 43) protocol was adopted by the American Association of Physicists in Medicine [12]. The dose of 85.0 Gy for the COMS trial was selected based upon expert consensus [9,11,13,14,15]. The COMS study showed that an eye-preserving, and potentially a vision-preserving, therapeutic regimen with iodine-125 plaque brachytherapy had a non-inferior mortality risk compared to enucleation up to 12 years following treatment [16].…”

“…The Greene melanoma rabbit model provided histological evidence of iodine-125 sparing adjacent tissue such as the lens and retina at more favorable rates than cobalt-60 brachytherapy [9]. The latter findings, in addition to a much safer profile by iodine-125 for both the patient and surgeon, given the ability to shield its radioactivity with merely a 0.5-mm gold sheet cover, led to the establishment of iodine-125 plaques as most widely used isotope for brachytherapy [11]. …”

Uveal Melanoma Regression after Brachytherapy: Relationship with Chromosome 3 Monosomy Status

“…The Collaborative Ocular Melanoma Study (COMS) further established radiation therapy as the primary treatment for medium-sized choroidal melanomas [2]. Various radioactive isotopes are used; with the gamma-radiating iodine 125 (I 125) [3] being more commonly used in American centers while the beta-radiating ruthenium 106 (Ru 106) is more commonly used in Europe [4,5]. Whichever radioisotope is used, regression in the thickness of the tumor is considered as one of the major factors denoting successful treatment [6].…”

Physics: Low-Energy Brachytherapy Physics

“…After comparing various isotopes (Ra-226, Au-198, Co-60, Ir-192, and I-125, as well as tantalum-182 and ruthenium-10), the Collaborative Ocular Melanoma Study chose I-125 ophthalmic plaque radiation therapy to treat medium-sized choroidal melanomas. In the study, 85 Gy was prescribed at the apex of tumor for 3-7 days at a dose rate of 0.42-1.05 Gy h −1 [35,36]. Some researchers chose to deliver the apical dose of 73.3 Gy over 5-7 days using Pd-103 and reported a favorable outcome [37][38][39].…”

Iodine-125 Brachytherapy for Uveal Melanoma: A Systematic Review of Radiation Dose

“…This dose was adjusted (originally 100.0 Gy) after the Task Group (TG 43) protocol was adopted by the American Association of Physicists in Medicine [12]. The dose of 85.0 Gy for the COMS trial was selected based upon expert consensus [9,11,13,14,15]. The COMS study showed that an eye-preserving, and potentially a vision-preserving, therapeutic regimen with iodine-125 plaque brachytherapy had a non-inferior mortality risk compared to enucleation up to 12 years following treatment [16].…”

“…The Greene melanoma rabbit model provided histological evidence of iodine-125 sparing adjacent tissue such as the lens and retina at more favorable rates than cobalt-60 brachytherapy [9]. The latter findings, in addition to a much safer profile by iodine-125 for both the patient and surgeon, given the ability to shield its radioactivity with merely a 0.5-mm gold sheet cover, led to the establishment of iodine-125 plaques as most widely used isotope for brachytherapy [11]. …”

Uveal Melanoma Regression after Brachytherapy: Relationship with Chromosome 3 Monosomy Status

“…The Collaborative Ocular Melanoma Study (COMS) further established radiation therapy as the primary treatment for medium-sized choroidal melanomas [2]. Various radioactive isotopes are used; with the gamma-radiating iodine 125 (I 125) [3] being more commonly used in American centers while the beta-radiating ruthenium 106 (Ru 106) is more commonly used in Europe [4,5]. Whichever radioisotope is used, regression in the thickness of the tumor is considered as one of the major factors denoting successful treatment [6].…”

Physics: Low-Energy Brachytherapy Physics

“…After comparing various isotopes (Ra-226, Au-198, Co-60, Ir-192, and I-125, as well as tantalum-182 and ruthenium-10), the Collaborative Ocular Melanoma Study chose I-125 ophthalmic plaque radiation therapy to treat medium-sized choroidal melanomas. In the study, 85 Gy was prescribed at the apex of tumor for 3-7 days at a dose rate of 0.42-1.05 Gy h −1 [35,36]. Some researchers chose to deliver the apical dose of 73.3 Gy over 5-7 days using Pd-103 and reported a favorable outcome [37][38][39].…”

Iodine-125 Brachytherapy for Uveal Melanoma: A Systematic Review of Radiation Dose

“…This dose was adjusted (originally 100.0 Gy) after the Task Group (TG 43) protocol was adopted by the American Association of Physicists in Medicine [12]. The dose of 85.0 Gy for the COMS trial was selected based upon expert consensus [9,11,13,14,15]. The COMS study showed that an eye-preserving, and potentially a vision-preserving, therapeutic regimen with iodine-125 plaque brachytherapy had a non-inferior mortality risk compared to enucleation up to 12 years following treatment [16].…”

“…The Greene melanoma rabbit model provided histological evidence of iodine-125 sparing adjacent tissue such as the lens and retina at more favorable rates than cobalt-60 brachytherapy [9]. The latter findings, in addition to a much safer profile by iodine-125 for both the patient and surgeon, given the ability to shield its radioactivity with merely a 0.5-mm gold sheet cover, led to the establishment of iodine-125 plaques as most widely used isotope for brachytherapy [11]. …”

Uveal Melanoma Regression after Brachytherapy: Relationship with Chromosome 3 Monosomy Status

“…The Collaborative Ocular Melanoma Study (COMS) further established radiation therapy as the primary treatment for medium-sized choroidal melanomas [2]. Various radioactive isotopes are used; with the gamma-radiating iodine 125 (I 125) [3] being more commonly used in American centers while the beta-radiating ruthenium 106 (Ru 106) is more commonly used in Europe [4,5]. Whichever radioisotope is used, regression in the thickness of the tumor is considered as one of the major factors denoting successful treatment [6].…”